Maxim analyst Michael Okunewitch initiated coverage of Alzamend Neuro with a Buy rating and $1.50 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALZN:
- Ault Inc. partner Alzamend initiates Phase I/IIa trial for Alzheimer’s vaccine
- Alzamend Neuro inititates Phase I/IIA Trial for LZN002 to treat dementia
- Alzamend Neuro receives Study May Proceed letter from FDA for Alzheimer’s study
- Alzamend Neuro announces completion of clinical portion of Phase IIA MAD trial